Defendant
1 case as defendant.
Company overview. Strides Pharma Global Pte. Ltd. (also styled "Strides Pharma Global Pte. Limited") is a Singapore private limited company incorporated on August 21, 2013, with its registered office at 3 Tuas South Avenue 4, Singapore (the complaint lists an additional address at The Central, Eu Tong Sen Street). It is the international headquarters and a step-down, wholly owned subsidiary of Strides Pharma Science Limited (formerly Strides Arcolab), a public generic-drug company listed on India's BSE (532531) and NSE (STAR) and headquartered in Bengaluru. The parent reports roughly 3,300–5,400 employees and about US$558 million in revenue (FY2025), with a market cap near US$950 million.
Products / operations. Strides Pharma Global functions as the group's international business hub, handling business development, sales and marketing, intellectual-property management, global supply chain, and regulatory affairs, and serves as holding company for international units (e.g., Strides Pharma International AG). It was granted International Headquarters Status by Singapore's EDB in 2015 and hosts a Singapore manufacturing facility supplying regulated markets. The parent group develops and manufactures generic finished-dosage pharmaceuticals — tablets, hard and soft capsules, liquids, topicals, and nasal sprays — sold in the U.S. and 100+ countries through U.S. affiliate Strides Pharma Inc. (Bridgewater, New Jersey).
Patent-litigation posture. Strides Pharma Global is an operating company, not an NPE. It has one tracked case, as defendant: Neurelis, Inc. v. Strides Pharma Global PTE Ltd. et al. (D. Del., filed July 31, 2026, No. 1:26-cv-00947-MN). This is a Hatch-Waxman ANDA suit filed in the District of Delaware, a standard venue for pharmaceutical patent litigation rather than an NPE-friendly forum.
Notable case context. Neurelis — a San Diego operating company affiliated with China Medical System Holdings — alleges that Strides' ANDA No. 221329 for a diazepam nasal spray infringes seven patents. The suit names Strides Global and its U.S. affiliate as defendants and has been related to consolidated actions Neurelis filed against other generic entrants (Lupin, Amneal, and Padagis).
ANDA case against Strides relating to ANDA No. 221329 and identified as a related action consolidated under lead case 1:24-cv-00562-MN. The Strides complaint expressly asserts the '414 patent among the asserted patents.